# About Semaglutide Reviews: An Independent Research Digest

> Reviews Semaglutide is an independent editorial project summarizing peer-reviewed clinical trial literature on Semaglutide. Not a clinic, not a vendor, not medical advice.

## What this site is

Reviews Semaglutide is an independent editorial project that publishes summaries of the peer-reviewed research literature on Semaglutide — specifically, the clinical trial record from the STEP, SUSTAIN, SELECT, and PIONEER programs and the supporting pharmacokinetic, safety, and mechanistic literature.

The 'reviews' in the domain name is editorial framing. This site reviews the evidence — meaning it reads the trials, weighs the findings against the limitations, names the gaps, and publishes the result. It does not review individual products. It does not review suppliers. It does not aggregate or publish user reviews of any kind. It is a research digest.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

## Scope and methodology

Coverage: FDA-approved semaglutide formulations as studied in registered clinical trials. Source types: Phase 3 trial publications from NEJM, The Lancet, JAMA, Nature Medicine, and Diabetes, Obesity and Metabolism; Phase 1 pharmacokinetic characterization studies; safety reviews from Frontiers in Endocrinology and related journals; 2024–2025 mechanistic literature reviews; post-marketing pharmacovigilance data.

Every quantitative claim is cited. Doses cited as the FDA-labeled doses studied in clinical trials — not as individual recommendations. Species is specified where findings are preclinical. Every citation maps to a numbered entry in the references index with a DOI and PubMed URL.

## Editorial independence

Reviews Semaglutide has no affiliation with any pharmaceutical manufacturer, prescriber, compounding pharmacy, or telehealth provider. No commercial relationship with any entity that manufactures, distributes, or prescribes semaglutide or any competing compound. No advertising from pharmaceutical companies. No sponsored content.

The domain modifier 'reviews' is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services or commercial relationships. This site does not offer treatment, consultation, or prescription services. It does not sell anything. It publishes editorial summaries of peer-reviewed research.

---

A trial-by-trial weighing of the semaglutide evidence record — STEP, SUSTAIN, SELECT, PIONEER — reported plainly, cited fully, and sold by no one.